Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $21.40.
Several research firms recently weighed in on CLBT. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, DA Davidson assumed coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective on the stock.
View Our Latest Stock Report on CLBT
Cellebrite DI Price Performance
Insider Buying and Selling
In related news, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the transaction, the chief executive officer directly owned 590,777 shares in the company, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David Barter sold 41,734 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the sale, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 158,191 shares of company stock valued at $2,479,438. Company insiders own 5.70% of the company’s stock.
Institutional Investors Weigh In On Cellebrite DI
Several hedge funds and other institutional investors have recently modified their holdings of CLBT. Portolan Capital Management LLC grew its position in shares of Cellebrite DI by 139.1% during the 3rd quarter. Portolan Capital Management LLC now owns 2,419,662 shares of the company’s stock worth $44,836,000 after buying an additional 1,407,818 shares in the last quarter. Granahan Investment Management LLC grew its holdings in Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock worth $48,721,000 after acquiring an additional 2,411,726 shares in the last quarter. Thematics Asset Management increased its position in Cellebrite DI by 22.6% during the 3rd quarter. Thematics Asset Management now owns 1,066,850 shares of the company’s stock valued at $19,769,000 after purchasing an additional 196,924 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Cellebrite DI by 28.6% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after purchasing an additional 300,000 shares during the period. Finally, Apis Capital Advisors LLC boosted its stake in shares of Cellebrite DI by 77.3% during the third quarter. Apis Capital Advisors LLC now owns 610,000 shares of the company’s stock valued at $11,303,000 after purchasing an additional 266,000 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
About Cellebrite DI
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Featured Articles
- Five stocks we like better than Cellebrite DI
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
